Therapeutic Response

EGFR Exon 20 (Insertion) status confers therapeutic sensitivity to Amivantamab in combination with Carboplatin and Pemetrexed in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Rybrevant (amivantamab-vmjw) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to amivantamab-vmjw in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test.
Rybrevant (amivantamab) [product information]. EMA. The European Medicines Agency (EMA) has authorized amivantamab in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutations.